Mall of America

Major Depressive Disorder Drugs Market Pipeline Report 2022: Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Major Depressive Disorder pipeline landscape.
  • The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

T Cell Surface Glycoprotein CD3 Epsilon Chain Drugs Market Analysis Report 2022: Developments by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "T Cell Surface Glycoprotein CD3 Epsilon Chain Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "T Cell Surface Glycoprotein CD3 Epsilon Chain Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development and features dormant and discontinued projects.

Circadian Rhythm Sleep Disorders Drugs Market Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Circadian Rhythm Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Circadian Rhythm Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Circadian Rhythm Sleep Disorders, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Adrenal Gland Cancer Drugs Pipeline Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Adrenal Gland Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adrenal Gland Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Adrenal Gland Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Double Homeobox Protein 4 Drugs Market Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Double Homeobox Protein 4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Double Homeobox Protein 4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) Drugs in Development report provides in depth analysis on Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) targeted therapeutics development and features dormant and discontinued projects.

T Cell Specific Surface Glycoprotein CD28 Drugs Pipeline Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "T Cell Specific Surface Glycoprotein CD28 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "T Cell Specific Surface Glycoprotein CD28 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development and features dormant and discontinued projects.

Cells Expressing T Cell Surface Glycoprotein CD5 Drugs Pipeline Market Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

The "Cells Expressing T Cell Surface Glycoprotein CD5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cells Expressing T Cell Surface Glycoprotein CD5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) targeted therapeutics development and features dormant and discontinued projects.

Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022

The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Key Points: 
  • The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

Heavy Metal Poisoning Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022

The "Heavy Metal Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Heavy Metal Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

IT'S O-FISH-IAL: OUTDOOR RETAILER CATCH CO. UNVEILS ITS FIRST EXPERIENTIAL RETAIL STORE, KARL'S FISHING & OUTDOORS

Retrieved on: 
Tuesday, June 14, 2022

CHICAGO, June 14, 2022 /PRNewswire/ --

Key Points: 
  • Located in WestBend, a 278,000-square-foot retail, office and dining destination in Fort Worth's University District with trails leading to the Trinity River, Karl's Fishing & Outdoors is a 2,500-square-foot storefront that combines retail with engaging, hands-on experiences.
  • The interactive store features best-in-class products for fishing and outdoor buffs.
  • Ideally located on the Clear Fork of the Trinity River, the store will host fishing lessons and meetups, including philanthropic events and entertainment.
  • Products include rods, reels, tackle, kits, tools, fly fishing gear, kayaks, apparel and outdoor lifestyle items.